Compare AU
Compare CURE vs. A200
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X S&P Biotech ETF (CURE) and the BetaShares Australia 200 ETF (A200). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
CURE | A200 | |
|---|---|---|
Popularity | Low | Medium |
Pearlers invested | 85 | 4,817 |
Median incremental investment | $616.00 | $1,076.25 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,431.36 | $3,547.96 |
Average age group | > 35 | 26 - 35 |
Key Summary
CURE | A200 | |
|---|---|---|
Strategy | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. | BetaShares Australia 200 ETF (ASX: A200) seeks to track the performance of the Solactive Australia 200 index before account fees, expenses, and taxes. The index tracks the largest 200 companies on the Australian Securities Exchange (ASX). |
Top 3 holdings | Viking Therapeutics Inc (3.00 %) Gilead Sciences Inc (2.76 %) Alnylam Pharmaceuticals Inc (2.76 %) | COMMONWEALTH BANK OF AUSTRALIA (10.03 %) BHP GROUP LTD (9.02 %) CSL LTD (5.83 %) |
Top 3 industries | Health Care (100.00 %) Other (10.24 %) | Financials (33.35 %) Materials (19.26 %) Health Care (8.80 %) |
Top 3 countries | United States (100.00 %) | |
Management fee | 0.45 % | 0.04 % |
Key Summary
CURE | A200 | |
|---|---|---|
Issuer | Global X | BetaShares |
Tracking index | S&P Biotechnology Select Industry | Solactive Australia 200 Index - AUD |
Asset class | ETF | ETF |
Management fee | 0.45 % | 0.04 % |
Price | $51.12 | $135.88 |
Size | $39.185 million | $6.155 billion |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 4.24 % | 5.25 % |
Market | ASX | ASX |
First listed date | 12/11/2018 | 08/05/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
CURE | A200 | |
|---|---|---|
Popularity | Low | Medium |
Pearlers invested | 85 | 4,817 |
Median incremental investment | $616.00 | $1,076.25 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,431.36 | $3,547.96 |
Average age group | > 35 | 26 - 35 |
Pros and Cons
CURE | A200 | |
|---|---|---|
Pros |
|
|
Cons |
|
|
CURE | A200 |
|---|---|
Higher exposure to US market | Lower exposure to US market |
Higher management fee | Lower management fee |
Lower price growth | Higher price growth |
Lower distribution yield | Higher distribution yield |